Showing 1601-1610 of 5603 results for "".
New Insights in the Management of HCM: Exploring the Clinical Spectrum
https://reachmd.com/programs/cme/new-insights-in-the-management-of-hcm-exploring-the-clinical-spectrum/33026/Explore personalized strategies in obstructive HCM, from diagnosis to treatment evolution, including real-world insights into cardiac myosin inhibitor use.When Topicals Fail: The New IPC Consensus Every Clinician Should Know
https://reachmd.com/programs/cme/when-topicals-fail-the-new-ipc-consensus-every-clinician-should-know/39967/Review IPC’s 2025 consensus guidance on reclassifying psoriasis severity and redefining failure of topical therapies.FXIa Remix! Keeping the Flow Without Missing a Beat
https://reachmd.com/programs/cme/fxia-remix-keeping-the-flow-without-missing-a-beat/54142/Examine factor XIa inhibition and OCEANIC-Stroke data on reducing the risk of recurrent ischemic stroke without increasing major bleeding.Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
https://reachmd.com/programs/cme/redefining-immunotherapy-access-integrating-subcutaneous-checkpoint-inhibitors-across-solid-tumors/56117/How are SC immune checkpoint inhibitors changing care in solid tumors? Hear a physician–nurse interview and explore implications for your practice.Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
https://reachmd.com/programs/cme/missing-the-window-in-ambulatory-patients-with-hfref-on-gdmt-strategies-for-cv-risk-reduction/48813/What is the optimal timing for adding evidence-based therapies beyond GDMT in patients with HFrEF? Explore this topic with Drs. Greene and Savarese.At the Intersection of DB, DED, MGD, and Other Forms of Blepharitis
https://reachmd.com/programs/cme/At-the-Intersection-of-DB-DED-MGD-and-Other-Forms-of-Blepharitis/56704/Join Drs. Devries and Koetting evaluate screening methods for accurate diagnosis of Demodex blepharitis and optimal treatment strategies for this condition.Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
https://reachmd.com/programs/cme/crossing-boundaries-cetp-inhibitors-and-the-next-frontier-in-lipid-control/33025/Exploring CETP inhibition as the next breakthrough in lipid lowering, cardiologists highlight mechanisms, trials, and its role as a future CV therapy.The Missed Diagnosis: A 45-Year-Old Software Engineer Who Complains of Dry Eyes
https://reachmd.com/programs/cme/the-missed-diagnosis-a-45-year-old-software-engineer-who-complains-of-dry-eyes/56705/Join Drs. Devries and Koetting evaluate screening methods for accurate diagnosis of Demodex blepharitis and optimal treatment strategies for this condition.Moving Beyond Lid Hygiene: Evidence-Based Treatment Strategies
https://reachmd.com/programs/cme/moving-beyond-lid-hygiene-evidence-based-treatment-strategies/56706/Join Drs. Devries and Koetting evaluate screening methods for accurate diagnosis of Demodex blepharitis and optimal treatment strategies for this condition.The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum
https://reachmd.com/programs/cme/the-hidden-threat-transforming-ckd-care-across-the-diabetes-spectrum/36523/Learn to identify hidden CKD risks in diabetes. Early diagnosis and new agents are reshaping T2D care today, with trials guiding future T1D treatment.